Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Jaguar Health, Inc. - Common Stock (NQ:JAGX)

1.415 +0.655 (+86.18%)

Streaming Delayed Price Updated: 1:25 PM EST, Jan 16, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	130,286,119
Open	1.060
Bid (Size)	1.410 (9,600)
Ask (Size)	1.420 (700)
Prev. Close	0.7600
Today's Range	1.010 - 1.870
52wk Range	0.6401 - 25.75
Shares Outstanding	171,350,166
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Keep an eye on the top gainers and losers in Friday's session. ↗

Today 12:30 EST

Via Chartmill

Friday's session: gap up and gap down stocks ↗

Today 10:30 EST

Via Chartmill

Performance

YTD	+41.9%	+41.9%
1 Month	+14.1%	+14.1%
3 Month	-33.3%	-33.3%
6 Month	-39.0%	-39.0%
1 Year	-93.5%	-93.5%

More News

Get insights into the top gainers and losers of Friday's pre-market session. ↗

Today 8:30 EST

Via Chartmill

Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts

January 14, 2026

Via ACCESS Newswire

Unusual volume stocks are being observed in Tuesday's session. ↗

January 13, 2026

Via Chartmill

Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million

January 12, 2026

Via ACCESS Newswire

Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication

January 06, 2026

Via ACCESS Newswire

Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

January 02, 2026

Via ACCESS Newswire

Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

December 15, 2025

Via ACCESS Newswire

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs

December 10, 2025

Via ACCESS Newswire

Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders

December 08, 2025

Via ACCESS Newswire

Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study

December 02, 2025

Via ACCESS Newswire

Get insights into the top gainers and losers of Monday's after-hours session. ↗

November 24, 2025

Via Chartmill

Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones

November 24, 2025

Via ACCESS Newswire

In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial

November 20, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 19, 2025

Via Benzinga

Tuesday's after hours session: top gainers and losers ↗

November 18, 2025

Via Chartmill

Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue

November 17, 2025

Via ACCESS Newswire

Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates

November 14, 2025

Via ACCESS Newswire

Jaguar Health Provides Recap of November 8, 2025 Presentation on Groundbreaking Results of Proof-of-Concept Study of Crofelemer for Treatment of Pediatric Intestinal Failure at NASPGHAN Annual Meeting

November 13, 2025

Via ACCESS Newswire

REMINDER: Initial Groundbreaking Results of Proof-of-Concept Study of Jaguar Health's Crofelemer for Treatment of Pediatric Intestinal Failure to be Presented November 8, 2025 at North American Society for Pediatric Gastroenterology, Hepatology and

November 06, 2025

Via ACCESS Newswire

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 24, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 09, 2025

Via Benzinga

Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID)

October 06, 2025

Via ACCESS Newswire

FDA-Authorized Expanded Access Programs Utilizing Jaguar Health's Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with Microvillus Inclusion Disease

September 30, 2025

Via ACCESS Newswire

Frequently Asked Questions

Is Jaguar Health, Inc. - Common Stock publicly traded?

Yes, Jaguar Health, Inc. - Common Stock is publicly traded.

What exchange does Jaguar Health, Inc. - Common Stock trade on?

Jaguar Health, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Jaguar Health, Inc. - Common Stock?

The ticker symbol for Jaguar Health, Inc. - Common Stock is JAGX on the Nasdaq Stock Market

What is the current price of Jaguar Health, Inc. - Common Stock?

The current price of Jaguar Health, Inc. - Common Stock is 1.415

When was Jaguar Health, Inc. - Common Stock last traded?

The last trade of Jaguar Health, Inc. - Common Stock was at 01/16/26 01:25 PM ET

What is the market capitalization of Jaguar Health, Inc. - Common Stock?

The market capitalization of Jaguar Health, Inc. - Common Stock is 242.46M

How many shares of Jaguar Health, Inc. - Common Stock are outstanding?

Jaguar Health, Inc. - Common Stock has 242M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.